Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
6990-06-3
Molecular formula
C31H48O6
Molecular weight
516.7 g/mol
Drug class
Steroidal-structure antibioticelongation factor G (EF-G) inhibitor
Mechanism of action
Binds bacterial elongation factor G (EF-G) and prevents its release from the ribosome after translocation, inhibiting protein synthesis and bacterial growth.
Indications / reported uses
Topical treatment of localised bacterial skin infections caused by susceptible Staphylococcus aureus, including impetigo and infected dermatitis, with authorised topical formulations
Systemic treatment of serious susceptible staphylococcal infections in selected jurisdictions and formulations; topical and systemic indications are not interchangeable
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fusidic Acid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fusidic Acid Permitted Daily Exposure (PDE) report (the Fusidic Acid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fusidic Acid Occupational Exposure Limit (OEL) report (the Fusidic Acid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.